Paraguay Expands Access to Second-Generation Dengue Vaccine

The Republic of Paraguay's Ministry of Public Health and Social Welfare announced today that the Dengue vaccination strategy, initially targeted at children in priority municipalities, is now being expanded to include individuals aged 39 and younger.

Announced on February 3, 2026, this decision is based on an epidemiological analysis conducted over recent years, which indicates a significant burden of Dengue not only among children but also among adolescents and young adults.

Between 2019 and 2024, the 20 to 39-year-old age group accounted for more than 108,000 Dengue cases in this South American country, reflecting one of the highest incidence rates recorded.

These findings support the extension of the second-generation, two-dose, Qdenga (TAK-003) vaccine, which protects against all four serotypes of the Dengue virus.

Paraguay says vaccination is a critical component of a comprehensive strategy that includes epidemiological surveillance and preventive measures to mitigate the impact of Dengue in the country.

Paraguay's neighbor, Brazil, recently announced it would focus on a newly approved third-generation, single-dose Butantan-DV vaccine for its residents.

Currently, Dengue vaccines are unavailable in the continental United States.